Rohan Paul 转述 intology 的自动化科研系统 Locus,称其在分子性质预测、Boltz-2 小分子效力预测微调和基于 BoltzGen、Boltz-2、ESMC、ESMFold2 的抗体设计工作流中超过 SOTA 专家方案。Locus 会提出实验、在 GPU 上并行跑多批实验并保留有效结果迭代,作者称其在分子预测上胜过 GPT-6 Astra 和 Claude Opus 5.5 智能体。
An AI system just designed better molecular models than the specialist tools built by the labs that own those models.
@intology’s Locus does a machine-learning researcher’s job:
> proposes experiments,
> runs many batches of them in parallel on GPUs
> keeps what works and repeats,
> now applied to drug and antibody design.
Locus beat GPT-6 Astra and Claude Opus 5.5 agents on molecular prediction
【引用 @intology】Locus sets the frontier for automating molecular design
Our automated research system Locus develops scientific AI models that outperform SOTA expert solutions
Unlocking the potential of scientific AI requires leveraging proprietary data. Locus achieves this autonomously 🧵👇
--
We test Locus across a number of tasks related to molecular scoring and design: training molecular property prediction models for a proprietary task, fine-tuning Boltz-2 to predict small-molecule potency, and building antibody design workflows around BoltzGen, Boltz-2, ESMC, and ESMFold2.
Each of these settings are real-world AI for science use cases, where tasks are often out-of-distribution for existing foundation models and limited in data, while featuring expensive and noisy evaluators. Compared to state-of-the-art baselines and LLM agents set to optimize these tasks, Locus achieves higher performance. Additionally, Locus generalizes better despite limited data, finds more sample efficient solutions, and explores a higher diversity of solutions.
Locus sets the frontier for automating molecular design Our automated research system Locus develops scientific AI models that outperform SOTA expert solutions Unlocking the potential of scientific AI requires leveraging proprietary data. Locus achieves this autonomously 🧵👇 -- We test Locus across a number of tasks related to molecular scoring and design: training molecular property prediction models for a proprietary task, fine-tuning Boltz-2 to predict small-molecule potency, and building antibody design workflows around BoltzGen, Boltz-2, ESMC, and ESMFold2. Each of these settings are real-world AI for science use cases, where tasks are often out-of-distribution for existing foundation models and limited in data, while featuring expensive and noisy evaluators. Compared to state-of-the-art baselines and LLM agents set to optimize these tasks, Locus achieves higher performance. Additionally, Locus generalizes better despite limited data, finds more sample efficient solutions, and explores a higher diversity of solutions.在 X 查看被引用的帖子
来源:Rohan Paul · x.com